Vascular remodeling and endothelial dysfunction in polycystic ovary syndrome: mechanisms, clinical markers, and therapeutic implications – a narrative review
- 15 July 2026
- journal article
- Published by Index Copernicus in Progress in Health Sciences
- Vol. 16 (1) , 59-70
Abstract
Introduction: Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders in women of reproductive age and is increasingly associated with an elevated risk of cardiometabolic complications. PCOS is linked to vascular changes, including endothelial dysfunction and subclinical atherosclerosis. These alterations may occur even in young women and before the development of overt cardio-vascular disease. Therefore, a comprehensive review of current evidence is needed to better understand the mechanisms of vascular remodeling in PCOS, identify clinically relevant vascular markers, and summarize potential therapeutic approaches aimed at reducing cardiovascular risk in this population.Purpose: To review current evidence on the pathophysiological mechanisms underlying vascular remodeling and endothelial dysfunction in women with PCOS, with particular emphasis on the role of hyperandrogenism. Additionally, the study aimed to summarize clinically relevant non-invasive vascular markers and evaluate available therapeutic approaches that may reduce cardiovascular risk in this population.Material and methods: This narrative review was based on a structured literature search conducted in PubMed/MEDLINE, Scopus, Web of Science, and Google Scholar. The search covered publications available from database inception to 31 March 2026 and focused on vascular remodeling, endothelial dysfunction, clinical vascular markers, and therapeutic approaches in PCOS. Eligible publications included original studies, reviews, meta-analyses, guidelines, and relevant mechanistic or preclinical studies.Conclusions: Hyperandrogenism-driven vascular remodeling significantly increases cardiovascular risk in specific PCOS phenotypes. Non-invasive vascular assessment and targeted therapies may support the clinical management of cardiovascular risk in these patients. Further research should focus on large-scale prospective studies, evaluate phenotype-specific cardiovascular trajectories, and validate emerging therapeutic targets to improve long-term outcomes.Keywords
This publication has 47 references indexed in Scilit:
- Endothelial function and peak heart rate in normal-weight women with polycystic ovary syndrome and normal-weight controlsEndocrine, 2025
- Effects of polyphenol in women with polycystic ovary syndrome: A systematic review and meta-analysis of randomized controlled trialsEuropean Journal of Obstetrics & Gynecology and Reproductive Biology, 2023
- A New Approach to Polycystic Ovary Syndrome and Related Cardio-metabolic Risk Factors: Dietary PolyphenolsCurrent Nutrition Reports, 2023
- Subclinical cardiovascular disease and polycystic ovary syndromeFertility and Sterility, 2022
- Quercetin derivatives: Drug design, development, and biological activities, a reviewEuropean Journal of Medicinal Chemistry, 2022
- Higher risk of type 2 diabetes in women with hyperandrogenic polycystic ovary syndromeFertility and Sterility, 2021
- Effect of quercetin on nonshivering thermogenesis of brown adipose tissue in high-fat diet-induced obese miceThe Journal of Nutritional Biochemistry, 2021
- Advanced glycation end products upregulate lysyl oxidase and endothelin-1 in human aortic endothelial cells via parallel activation of ERK1/2–NF-κB and JNK–AP-1 signaling pathwaysCellular and Molecular Life Sciences, 2015
- Imbalanced circulating matrix metalloproteinases in polycystic ovary syndromeMolecular and Cellular Biochemistry, 2011
- Hemodynamic alterations and wall properties in large arteries of young, normotensive, and non-obese women with polycystic ovary syndromeJournal of Endocrinological Investigation, 2008